ClinicalTrials.gg
Active, not recruitingNCT03836261AMPLIFYUpdated Oct 5, 2026

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

A Phase 3 interventional study of Acalabrutinib and Venetoclax in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Active, not recruiting at 169 sites in 27 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Updated Oct 5, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
984
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
Largest of 39
984 · median 61
Started
2019
with 3 others
Phase 3
9 of 39
1 open now
Primary completion
2027-04
later than 15 of 27 live
Registered
13th of 39
by date
Lead sponsor
9 of 39
Acerta Pharma BV

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment, is one of 4 that started in 2019, is one of 9 in phase 3, reaches primary completion later than 15 of the 27 other live ones, and was the 13th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL

Read the detailed description

This randomized, global, multicenter, open-label, Phase 3 study will evaluate the efficacy and safety of AV and AVG versus chemoimmunotherapy (FCR or BR) in subjects with previously untreated CLL without del(17p) or TP53. Subjects will be randomized in a 1:1:1 ratio into 3 arms through a block stratified randomization procedure.

The study includes screening (35 days), treatment (from randomization until study drug discontinuation) and follow-up phase.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
  • Chronic Leukemia Lymphocytic
  • Leukemia
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥18 years of age.
  • (ECOG) performance status of 0-2.
  • Diagnosis of CLL that meets published diagnostic criteria (Hallek et al. 2018)
  • Active disease per IWCLL 2018 criteria that requires treatment.
  • Participants must use highly effective throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Any prior CLL-specific therapies.
  • Detected del(17p) or TP53 mutation.
  • Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (e.g., Richter's transformation, prolymphocytic leukemia [PLL], or diffuse large B cell lymphoma [DLBCL]), or central nervous system (CNS) involvement by leukemia.
  • History of confirmed progressive multifocal leukoencephalopathy (PML).
  • Received any drug within 30 days before first dose of study drug.
  • Major surgical procedure within 30 days before the first dose of study drug.
  • Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease. Note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study.
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  • Received a within 28 days of first dose of study drug.
  • Known history of infection with (HIV).
  • Serologic status reflecting active or C infection.
  • History of known or anaphylactic reactions to study drugs or .
  • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
  • Known bleeding disorders.
  • Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.
  • Female participants must not be breastfeeding or pregnant.
  • Concurrent participation in another therapeutic clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
984 participants (actual)

Study arms

  • Experimental
    Acalabrutinib, Venetoclax

    Acalabrutinib in combination with Venetoclax

    Drug: Acalabrutinib · Drug: Venetoclax

  • Experimental
    Acalabrutinib, Venetoclax, Obinutuzumab

    Acalabrutinib in combination with Venetoclax with Obinutuzumab

    Drug: Acalabrutinib · Drug: Venetoclax · Drug: Obinutuzumab

  • Active comparator
    Chemoimmunotherapy

    Chemoimmunotherapy FCR: Fludarabine, Cyclophosphamide and Rituximab BR: Bendamustine and Rituximab

    Drug: Chemoimmunotherapy

Interventions

  • Acalabrutinib,

    Also known as: Calquence (acalabrutinib)

  • Venetoclax

    Also known as: Venclyxto, Venclexta

  • DrugChemoimmunotherapy

    fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)

  • Obinutuzumab

    Also known as: Gazyva, Gazyvaro

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of acalabrutinib with venetoclax (Arm A) compared to chemoimmunotherapy fludarabine/cyclophosphamide/rituximab [FCR] or bendamustine/rituximab [BR] (Arm C): PFS

    Progression-free survival (PFS) after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the Independent Review Committee (IRC) according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria

    Time frame: 6 years

Secondary outcomes

  1. To evaluate the efficacy of acalabrutinib with venetoclax in combination with obinutuzumab (Arm B) compared with FCR or BR (Arm C): PFS

    PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the IRC assessment and investigator assessment

    Time frame: 6 years

  2. To evaluate the efficacy of acalabrutinib with venetoclax (Arm A) compared with FCR or BR (Arm C): PFS defined the same as above per investigator assessment.

    PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the IRC assessment and investigator assessment

    Time frame: 6 years

07

Study locations

169 sites
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Redondo Beach, California 90277, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    New Orleans, Louisiana 70056, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Fort Sam Houston, Texas 78234, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Buenos Aires, 1114, Argentina
  • Research Site
    Capital Federal, 1118, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1426ANZ, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Krems, 3500, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Vienna, 1140, Austria
  • Research Site
    Goiânia, 74605-020, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Rio de Janeiro, 20230-130, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    São Paulo, 01236-030, Brazil
  • Research Site
    São Paulo, 01308-050, Brazil
  • Research Site
    São Paulo, 05403-010, Brazil
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400037, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110134, China
  • Research Site
    Tianjin, 301600, China
  • Research Site
    Ürümqi, 830054, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Olomouc, 779 00, Czechia
  • Research Site
    Ostrava - Poruba, 70852, Czechia
  • Research Site
    Plzen - Lochotin, 304 60, Czechia
  • Research Site
    Prague, Czechia
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Roskilde, 4000, Denmark
  • Research Site
    Montpellier, 34090, France
  • Research Site
    Paris, 75013, France
  • Research Site
    Paris, 75015, France
  • Research Site
    Paris, 75475, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Paderborn, 33098, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1088, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Haifa, 31999, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Jerusalem, Israel
  • Research Site
    Petah Tikva, 49100, Israel

Showing the first 100 of 169 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, Tedeschi A, Owen C, Skarbnik A, Lysak D, Eom KS, Simkovic M, Pavlovsky MA, Kater AP, Eichhorst B, Miller K, Munugalavadla V, Yu T, de Borja M, Ghia P; AMPLIFY investigators; AMPLIFY Investigators. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. N Engl J Med. 2025 Feb 20;392(8):748-762. doi: 10.1056/NEJMoa2409804. Epub 2025 Feb 5. PubMed 39976417 ↗
  • Alfaifi A, Bahashwan S, Alsaadi M, Ageel AH, Ahmed HH, Fatima K, Malhan H, Qadri I, Almehdar H. Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies. Adv Hematol. 2024 Nov 12;2024:5948170. doi: 10.1155/2024/5948170. eCollection 2024. PubMed 39563886 ↗
  • Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14. PubMed 34534514 ↗
  • Gordon MJ, Danilov AV. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. Ther Adv Hematol. 2021 Jan 30;12:2040620721989588. doi: 10.1177/2040620721989588. eCollection 2021. PubMed 33796237 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Apr 2027, 98 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's planned 98 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Jan 2027 → Apr 2027 and completion Jan 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Feb 11, 2019
StartActual
Feb 25, 2019
Primary completionEst.
Apr 30, 2027was Jan 2027
CompletionEst.
Apr 30, 2027was Jan 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
27 sites added, 28 sites removed
Show 27 added (5 France, 3 Brazil, 2 China, 2 Czechia, 2 Israel, 2 Italy, 2 Netherlands, 2 Poland, 2 Russia, 2 Taiwan, 1 Argentina, 1 Canada, 1 Sweden)
  • Research Site · Ciudad de Buenos Aires, Argentina
  • Research Site · Goiânia, Brazil
  • Research Site · São Paulo, Brazil
  • Research Site · São Paulo, Brazil
  • Research Site · Québec, Canada
  • Research Site · Ürümqi, China
  • Research Site · Xi'an, China
  • Research Site · Hradec Králové, Czechia
  • Research Site · Prague, Czechia
  • Research Site · Montpellier, France
  • Research Site · Paris, France
  • Research Site · Rennes, France
  • Research Site · Rouen, France
  • Research Site · Toulouse, France
  • Research Site · Petah Tikva, Israel
  • Research Site · Tel Litwinsky, Israel
  • Research Site · Milan, Italy
  • Research Site · Milan, Italy
  • Research Site · 's-Hertogenbosch, Netherlands
  • Research Site · Almere Stad, Netherlands
  • Research Site · Lodz, Poland
  • Research Site · Wroclaw, Poland
  • Research Site · Saint Petersburg, Russia
  • Research Site · Saint Petersburg, Russia
  • Research Site · Gothenburg, Sweden
  • Research Site · Kaohsiung City, Taiwan
  • Research Site · Tainan, Taiwan
Show 28 removed
  • Research Site · Buenos Aires, Argentina
  • Research Site · Goiania, Brazil
  • Research Site · Sao Paulo, Brazil
  • Research Site · Sao Paulo, Brazil
  • Research Site · Quebec, Canada
  • Research Site · Urumchi, China
  • Research Site · Xian, China
  • Research Site · Hradec Kralove, Czechia
  • Research Site · Praha, Czechia
  • Research Site · Montpellier Cedex 5, France
  • Research Site · Paris Cedex 10, France
  • Research Site · Rennes Cedex 9, France
  • Research Site · Rouen Cedex 1, France
  • Research Site · Toulouse Cedex 9, France
  • Research Site · Petah Tiqva, Israel
  • Research Site · Tel Hashomer, Israel
  • Research Site · Milano, Italy
  • Research Site · Milano, Italy
  • Research Site · Almere, Netherlands
  • Research Site · Den Bosch, Netherlands
  • Research Site · Wrocław, Poland
  • Research Site · Łódź, Poland
  • Research Site · Saint-Petersburg, Russian Federation
  • Research Site · St Petersburg, Russian Federation
  • Research Site · Goteborg, Sweden
  • Research Site · Kaohsiung, Taiwan
  • Research Site · Tainan City, Taiwan
  • Research Site · Taoyuan City, Taiwan
Oct 5, 2026
Primary completion
Jan 31, 2027→Apr 30, 2027
Oct 5, 2026
Study completion
Jan 31, 2027→Apr 30, 2027
Oct 5, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 39976417 ↗
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 39976417 ↗
    27 sites added, 28 sites removed
    Show 27 added (5 France, 3 Brazil, 2 China, 2 Czechia, 2 Israel, 2 Italy, 2 Netherlands, 2 Poland, 2 Russia, 2 Taiwan, 1 Argentina, 1 Canada, 1 Sweden)
    • Research Site · Ciudad de Buenos Aires, Argentina
    • Research Site · Goiânia, Brazil
    • Research Site · São Paulo, Brazil
    • Research Site · São Paulo, Brazil
    • Research Site · Québec, Canada
    • Research Site · Ürümqi, China
    • Research Site · Xi'an, China
    • Research Site · Hradec Králové, Czechia
    • Research Site · Prague, Czechia
    • Research Site · Montpellier, France
    • Research Site · Paris, France
    • Research Site · Rennes, France
    • Research Site · Rouen, France
    • Research Site · Toulouse, France
    • Research Site · Petah Tikva, Israel
    • Research Site · Tel Litwinsky, Israel
    • Research Site · Milan, Italy
    • Research Site · Milan, Italy
    • Research Site · 's-Hertogenbosch, Netherlands
    • Research Site · Almere Stad, Netherlands
    • Research Site · Lodz, Poland
    • Research Site · Wroclaw, Poland
    • Research Site · Saint Petersburg, Russia
    • Research Site · Saint Petersburg, Russia
    • Research Site · Gothenburg, Sweden
    • Research Site · Kaohsiung City, Taiwan
    • Research Site · Tainan, Taiwan
    Show 28 removed
    • Research Site · Buenos Aires, Argentina
    • Research Site · Goiania, Brazil
    • Research Site · Sao Paulo, Brazil
    • Research Site · Sao Paulo, Brazil
    • Research Site · Quebec, Canada
    • Research Site · Urumchi, China
    • Research Site · Xian, China
    • Research Site · Hradec Kralove, Czechia
    • Research Site · Praha, Czechia
    • Research Site · Montpellier Cedex 5, France
    • Research Site · Paris Cedex 10, France
    • Research Site · Rennes Cedex 9, France
    • Research Site · Rouen Cedex 1, France
    • Research Site · Toulouse Cedex 9, France
    • Research Site · Petah Tiqva, Israel
    • Research Site · Tel Hashomer, Israel
    • Research Site · Milano, Italy
    • Research Site · Milano, Italy
    • Research Site · Almere, Netherlands
    • Research Site · Den Bosch, Netherlands
    • Research Site · Wrocław, Poland
    • Research Site · Łódź, Poland
    • Research Site · Saint-Petersburg, Russian Federation
    • Research Site · St Petersburg, Russian Federation
    • Research Site · Goteborg, Sweden
    • Research Site · Kaohsiung, Taiwan
    • Research Site · Tainan City, Taiwan
    • Research Site · Taoyuan City, Taiwan
    Primary completion Jan 31, 2027→Apr 30, 2027
    Study completion Jan 31, 2027→Apr 30, 2027
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03836261
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Feb 11, 2019
Start date
Feb 25, 2019
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Jennifer Brown
principal investigator · Dana Farber Mass General Brigham Cancer Care Inc
Barbara Eichhorst
principal investigator · Universitätsklinikum Köln
Arnon Kater
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Paolo Ghia
principal investigator · OSPEDALE S. RAFFAELE - MILANO
John Seymour
principal investigator · Peter MacCallum Cancer Ctr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Venetoclax · Obinutuzumab

Start the discussion